A PHASE 1, FIRST-IN-HUMAN STUDY OF IMMUNOPET IMAGING OF PD-L1 IN TUMORS USING 89ZR-DFO-REGN3504, AN ANTI-PD-L1 TRACER FOR POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH ADVANCED THORACIC MALIGNANCIES
Sponsor: |
Regeneron |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS0159 |
U.S. Govt. ID: |
NCT03746704 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study involves research and is conducted to determine how safe and effective a study drug called 89Zr-DFO-REGN3504 is. 89Zr-DFO-REGN3504 is investigational, which means it has not been approved by any health authority (like the Food and Drug Administration - FDA) for marketing for any condition. 89Zr-DFO-REGN3504 is being studied as an agent for imaging tumors, and will be administered by infusion (through the vein). Cancers include: esophageal cancer, lung cancer, and stomach cancer.
This study is closed
Investigator
Akiva Mintz, MD, PhD
Are you 18 years or older? |
Yes |
No |
Do you have an advanced thoracic malignancy? |
Yes |
No |